Special to DG News
WASHINGTON, DC — April 29, 2002 — Use of tacrolimus after renal transplantation appears to increase significantly the risk for diabetes mellitus, while use of mycophenolate mofetil appears to decrease the risk.
At the American Transplant Congress, Transplant 2002 in Washington, DC, here today, researchers reported a 69 percent increase in the relative risk for post-transplant diabetes mellitus. Mycophenolate mofetil (MMF), however, was associated with a slight decrease (15 percent) in RR.
Bertram L. Kasiske, MD, of the University of Minnesota, Minneapolis, United States, said the incidence of PTDM is 14.9 percent at 12 months post-transplant and 22.3 percent at 36 months.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!